Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of TDM-180935 in Healthy Men
NCT05525468Phase 1Completed
- Sponsor
- TechnoDerma Medicines Inc.
- Start
- Feb 2023
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tdm-180935 in atopic dermatitis (AD) (4 arms), sponsored by TechnoDerma Medicines Inc. Primary endpoints: Incidence of local and systemic Adverse Events at 42 days, Presence and severity of local skin reactions at 42 days and 6 more. Started Feb 2023; status: completed.
02
Drugs
tdm-180935
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05525468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05525468.